Stephens initiated coverage of Ideaya Biosciences (IDYA) with an Overweight rating and $51 price target The firm is adding to its Biotechnology research coverage with a focus on targeted protein degradation, or TPD, technology and commercial and clinical-stage rare disease-focused companies. Ideaya’s lead asset is in Phase 2/3 potential registrational trials for the treatment of metastatic uveal melanoma, or MUM, and it has a “robust pipeline” in development for multiple solid tumor indications, the analyst tells investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences appoints Stu Dorman as chief commercial officer
- Ideaya Biosciences nominates IDE034 as development candidate, exercises option
- Biocytogen announces Ideaya’s nomination of development candidate IDE034
- Dollar Tree downgraded, eBay upgraded: Wall Street’s top analyst calls
- Leerinks downgrades Ideaya Biosciences pending clarity on key programs